I found this article dated September 10, 2004 in the online edition of The New Zealand Herald. (John Thompson of course is Delcath's lead investigator in Sydney. Maybe someone else can post the URL--I could only get an incomplete one. Title is "Melanoma breakthrough hailed." It does not deal with Delcath, but may be of interest: "A treatment for melanoma which is less invasive than surgery and allows patients to recover faster has been found to stop the disease recurring in half the people treated. Professor John Thompson, of the Sydney Melanoma Unit, told a surgeons' conference in Auckland yesterday that the treatment, used on people suffering recurrent limb melanoma, involved injecting conventional chemotherapy drugs into the affected area rather than the whole body. Tourniquets confined the drugs to the leg or arm. The procedure, which had been used for a number of years, was simple and safe and offered a promising alternative to people with recurrent melanoma unable to have surgery because of how advanced or extensive the disease was, he said." To summarize, out of 350 patients studied over 10 years. 50% achieved complete remission, as opposed to 1% with oridinary drug treatment. The Australian study is to become part of an international trial.